StockData
Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP) company profile

CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$3.01−0.37 (-10.81%)

Close on Nov 17, 2026Market cap $58.22MP/E –Yield –

About Corbus Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Corbus Pharmaceuticals Holdings is a clinical-stage biopharmaceutical firm that develops treatments for oncology and metabolic conditions. Its pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4 to treat solid tumors such as cervical, urothelial, and head and neck cancers. It also develops CRB-913, an oral cannabinoid receptor inverse agonist for obesity management. Because its programs remain in clinical testing, Corbus has no commercial products or commercial customers; its development efforts target patients suffering from advanced solid cancers and obesity.

The text does not state the location of the company's headquarters. Corbus conducts clinical trials in the United States and Europe, with partner studies active in China. The company holds licensing rights across the United States, Canada, Europe, the United Kingdom, and Australia for its lead cancer drug, alongside global rights for its obesity candidate. Corbus does not own manufacturing facilities, instead utilizing third-party contract manufacturers and partner agreements to supply compounds for its research programs.

Summary of the business section of Corbus Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Corbus Pharmaceuticals Holdings, Inc.
Founded
2009
Headquarters
Norwood, MA
Address
500 River Ridge Drive 02062
Phone
(617) 963-0103
Employees
36, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
EISNERAMPER LLP, Iselin, New Jersey

Stock & identifiers

Ticker
CRBP
Exchange
Nasdaq
IPO date
Oct 27, 2014
Shares outstanding
19M, Aug 4, 2026
Public float
$67.80M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-30 reverse, Feb 14, 2023
SEC CIK
1595097
CUSIP
21833P301
ISIN
US21833P3010
FIGI
BBG0078PJKQ7
Share class FIGI
BBG0078PJKP8
LEI
529900MX6XCNZC7MM155
EIN
46-4348039

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Yuval CohenChief Executive Officer, Director157,316
Leonardo Viana NicacioChief Medical Officer58,333
Nishant C. SaxenaChief Business Officer77,900
Sean F. MoranChief Financial Officer84,694
Dominic SmethurstChief Medical Officer89,790
Ian HodgsonChief Operating Officer51,080
Yong BenDirector9,383
John Kenneth JenkinsDirector3,833
Anne AltmeyerDirector7,579
Winston KungDirector12,140
Brent PfeiffenbergerDirector7,500
Rachelle Suzanne JacquesDirector11,383
Alan F. HolmerDirector10,629

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.75M$2.59M$1.79M$244–
FY2024$4.25M$4.07M$2.66M$354–
FY2023$1.14M$1.36M$778.56K$181–
FY2022$1.44M$406.59K$771.21K$9–
FY2021$4.86M$1.40M$930.36K$49–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Yuval Cohen
Chief Executive Officer
$646.57K$373.68K$666.70K$2.04M$23.88K$3.75M-12%
Sean Moran
Chief Financial Officer
$481.14K$185.38K$269.23K$824.45K$29.23K$1.79M-26%
Dominic Smethurst
Chief Medical Officer
$519.31K$168.08K$266.29K$812.87K$33.60K$1.80M-38%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“We had 36 full-time employees at December 31, 2025.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?